Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

UBE2E3 Supports Survival of Leukemia Stem Cells By Regulation of Polycomb Repression Complex (PRC) 1.1

Vika Miller, Ayat Hija, Mohamed Abdal-Rhaman, Noa Gross Even-Zohar, Michal Saltsman, Aaron Botham, Arnon Haran, Shlomzion Aumann, Vladimir Vainstein, Moshe E Gatt, Brian Raught, Aaron D Schimmer, Boaz Nachmias

Blood (2024) 144 (Supplement 1): 5714.

https://doi.org/10.1182/blood-2024-193438

Published: 2024

Journal Articles

DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms

Arnon Haran, Avital Wasserstrom, Shlomzion Aumann, Vladimir Vainstein, Romi Kazoom, Batia Roth Jelinek, Ariela Arad, Noa Buchman, Ela Shai, Yossi Kalish, Moshe E Gatt, Eran Zimran

Blood (2024) 144 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2024-209783

Published: 2024

Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2023-173317

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Vladimir Vainstein, Arnon Haran, Boaz Nachmias

Blood (2023) 142 (Supplement 1): 4212.

https://doi.org/10.1182/blood-2023-179194

Published: 2023

Journal Articles

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic

Shlomzion Aumann, Uria Tsubary, Sarah Israel, Dina Ben Yehuda, David Lavie, Neta Goldschmidt, Vladimir Vainstein, Diana Libster, Revital Saban, Adir Shaulov, Batia Avni, Boaz Nachmias, Sigal Grisariu, Ora Paltiel, Moshe Gatt, Eran Zimran

Blood (2021) 138 (Supplement 1): 4088.

https://doi.org/10.1182/blood-2021-148512

Published: 2021

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Boaz Nachmias, MD PhD, Geremy Godefroy, MD, Chezi Ganzel, MD, Neta Goldschmidt, MD, Eyal Rozenbach, MD, Rachel Bar-Shalom, MD, Diana Libster, MD, Vladimir Vainstein, MD

Blood (2019) 134 (Supplement_1): 5358.

https://doi.org/10.1182/blood-2019-121473

Published: 2019

Journal Articles

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Youn H Kim, MD, Richard T. Hoppe, MD, Alain H Rook, MD, Amit Maity, MD PhD, Larisa J Geskin, MD, David P Horowitz, MD, Genet Finnegan, MHS, PA-C, Michael Khodadoust, MD PhD, Wen-Kai Weng, MD PhD, Analuisa Lares, ANP, BSN, RN, Eric Ki Jun Hong, BS, Marie Buchanan, RN, Vernon Ma, BS, Hue Kha, BS, Chris E Lawrence, PhD, Vladimir Vainstein, MD, Lena A Basile, PhD JD

Blood (2016) 128 (22): 4165.

https://doi.org/10.1182/blood.V128.22.4165.4165

Published: 2016

Journal Articles

Recombinant Human IL-12 Promotes NK Cell Migration: Increased CXCL10, Co-Receptors IL-12Rβ2 and CXCR3, and Bright CD56 NK Cells In Healthy Human Subjects

Simmy Thomas, PhD, Chris E. Lawrence, PhD, Vernon Mar, MS, Hue Kha, MS, Vladimir Vainstein, MD, MS, Mamata Gokhale, PhD, Lena A. Basile, PhD, JD

Blood (2013) 122 (21): 3481.

https://doi.org/10.1182/blood.V122.21.3481.3481

Published: 2013

Journal Articles

Adverse Events During Intensive Induction Chemotherapy For Acute Myeloid Leukemia (AML) Or High-Grade Myelodysplastic Syndromes (MDS)

Sarah A. Buckley, MD, Megan Othus, PhD, Vladimir Vainstein, MD MSc, Janis L. Abkowitz, MD, Elihu H. Estey, MD, Roland B. Walter, MD, PhD

Blood (2013) 122 (21): 3899.

https://doi.org/10.1182/blood.V122.21.3899.3899

Published: 2013

Journal Articles

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

Vladimir Vainstein, Christopher A. Eide, Thomas O’Hare, Ofir Shukron, Brian J. Druker

Blood (2013) 122 (19): 3331–3334.

https://doi.org/10.1182/blood-2012-08-452409

Published: 2013

Includes: Supplemental data

Journal Articles

Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia

Vladimir Vainstein, MD MSc, Sarah A. Buckley, MD, Shukron Ofir, MSc, Elihu H. Estey, MD, Janis L Abkowitz, MD, Brent L. Wood, MD, PhD, Roland B. Walter, MD, PhD

Blood (2012) 120 (21): 3551.

https://doi.org/10.1182/blood.V120.21.3551.3551

Published: 2012

Journal Articles

Combining Dose-Response Slope with in Vitro Sensitivity to ABL Tyrosine Kinase Inhibitors As an Improved Correlative Metric for Predicting Clinical Response in Chronic Myeloid Leukemia

Vladimir Vainstein, MD MSc, Christopher A. Eide, Thomas O'Hare, PhD, Brian J. Druker

Blood (2012) 120 (21): 1670.

https://doi.org/10.1182/blood.V120.21.1670.1670

Published: 2012

Journal Articles

Predicting Duration of Neutropenia After Successful Intensive Induction Chemotherapy for Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndromes

Sarah A. Buckley, MD, Vladimir Vainstein, MD MSc, Janis L. Abkowitz, MD, Elihu H. Estey, MD, Roland B. Walter, MD, PhD

Blood (2012) 120 (21): 4336.

https://doi.org/10.1182/blood.V120.21.4336.4336

Published: 2012

Journal Articles

Clinical Validation of a Physiologically-Based Computer Model of Human Granulopoiesis and Its Use for Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor (GCSF).

Vladimir Vainstein, MD, MSc, Yuval Ginosar, PhD, Meir Shoham, MSc, Anton Ianovski, MSc, Alexander Rabinovich, Yuri Kogan, Vera Selitser, Samuel Ariad, MD, Stephen Chan, MD, Zvia Agur, PhD

Blood (2006) 108 (11): 3848.

https://doi.org/10.1182/blood.V108.11.3848.3848

Published: 2006

NARROW

UBE2E3 Supports Survival of Leukemia Stem Cells By Regulation of Polycomb Repression Complex (PRC) 1.1

DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Recombinant Human IL-12 Promotes NK Cell Migration: Increased CXCL10, Co-Receptors IL-12Rβ2 and CXCR3, and Bright CD56 NK Cells In Healthy Human Subjects

Adverse Events During Intensive Induction Chemotherapy For Acute Myeloid Leukemia (AML) Or High-Grade Myelodysplastic Syndromes (MDS)

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia

Combining Dose-Response Slope with in Vitro Sensitivity to ABL Tyrosine Kinase Inhibitors As an Improved Correlative Metric for Predicting Clinical Response in Chronic Myeloid Leukemia

Predicting Duration of Neutropenia After Successful Intensive Induction Chemotherapy for Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndromes

Clinical Validation of a Physiologically-Based Computer Model of Human Granulopoiesis and Its Use for Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor (GCSF).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only